EUVIMEDEUVIMED entdecken
Crossref

Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy

Tomas Milota, Jitka Smetanova, Hana Zelena, Michal Rataj, Jan Lastovicka, Jirina Bartunkova

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.111159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Tomas Milota und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Czech Republic. Electronic address: tomas.milo…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Agentura Pro Zdravotnický Výzkum České Republiky, Ministry of Health of the Czech Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Specific antibodies are important for post-vaccination and post-infection immune responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The role of antibodies in preventing and treating Coronavirus disease 2019 (COVID-19) in high-risk populations has been highlighted through the use of virus-specific monoclonal antibodies, which has raised the question of immunoglobulin replacement therapy (IRT) used in immunocompromised patients. METHODS: Virus-specific anti-receptor-binding domain (RBD) and anti-nucleocapsid protein (NCAP) antibodies (assessed using a chemiluminescence assay and virus-neutralizing antibodies (virus neutralization test against Delta and Omicron variants)) were analyzed in 20 batches of 10 % (100 mg/mL) immunoglobulin solutions for intravenous IRT from two commercially available producers between January 2022 and March 2023 for clinical use. RESULTS: Anti-RBD and anti-NCAP antibodies were detected in all 20 batches of assessed IRT solutions (mean concentrations of 2817 IU/mL and 2380 IU/mL, respectively). Notably, the concentration of the virus-specific antibodies increased continuously during the follow-up period (from 822.5 IU/mL to 4066.4 IU/mL and 102 IU/mL to 3455.9 IU/mL). These antibodies demonstrated high virus-neutralizing activity against the Delta variant (mean titers of 436 and 325) but were limited to the Omicron variant (mean titers 78 and 70). The differences observed between the two brands were not statistically significant. CONCLUSION: IRT solutions contain high concentrations of anti-SARS-CoV-2 specific antibodies, which may prevent COVID-19; however, the efficacy can be influenced by variable virus-neutralizing activities against different viral strains. Therefore, appropriate IRT should be combined with other approaches, such as vaccination or pre- and post-exposure prophylaxis. Passively transmitted specific antibodies may also lead to false-positive serological test results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansSARS-CoV-2Immunization, PassiveAntibodies, ViralNucleocapsid ProteinsReceptors, VirusAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19Delta variantImmunoglobulin replacement therapyNucleocapsid proteinOmicron variantReceptor-binding DomainSARS-COV-2

Substanzen

Antibodies, ViralNucleocapsid ProteinsReceptors, VirusAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Czech Republic. Electronic address: tomas.milota@fnmotol.cz.
  • Department of Immunology, Second Faculty of Medicine Charles University and Motol University Hospital, Czech Republic.
  • Department of Virology, Public Health Institute, Ostrava, Czech Republic.

Förderung

  • Agentura Pro Zdravotnický Výzkum České Republiky
  • Ministry of Health of the Czech Republic

Zitieren

APA

Milota, T., Smetanova, J., Zelena, H., Rataj, M., Lastovicka, J., & Bartunkova, J. (2023). Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111159

Vancouver

Milota T, Smetanova J, Zelena H, Rataj M, Lastovicka J, Bartunkova J. Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.111159

BibTeX
@article{Milota2023,
  author = {Milota, Tomas and Smetanova, Jitka and Zelena, Hana and Rataj, Michal and Lastovicka, Jan and Bartunkova, Jirina},
  title = {Content and specificity of the Anti-SARS-CoV-2 antibodies in solutions for immunoglobulin replacement therapy},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.111159}
}
Kostenlos starten →